BC Launches National Pharmacare on March 1, 2026: What It Means for Drug Coverage

What the Federal Pharmacare Deal Covers

Under the Canada Pharmacare Act (Bill C-64), the federal government agreed to fund a first wave of drug categories through partnerships with willing provinces. British Columbia was the first to sign and implement the agreement. The covered categories include:

• Diabetes medications — including insulin, metformin, and select SGLT2 inhibitors and GLP-1 receptor agonists approved for type 2 diabetes management
• Contraceptives — a broad range of hormonal and non-hormonal options
• Hormone therapy — for menopause management

The BC Ministry of Health estimates that over 500,000 British Columbians will benefit in the first year, with the largest gains felt by residents who previously had no private drug coverage.

Is Ozempic Covered Under BC Pharmacare?

This is the question most Canadians are asking — and the answer requires nuance. Ozempic (semaglutide 0.5mg and 1mg) is a GLP-1 receptor agonist approved in Canada for type 2 diabetes management. When prescribed for that indication, it may qualify for coverage under the new pharmacare framework depending on the specific formulary BC adopts.

However, Ozempic prescribed off-label for weight management is not covered. Similarly, Wegovy (semaglutide 2.4mg), which is approved specifically for chronic weight management, is not part of the current pharmacare coverage list. The federal formulary focuses on the diabetes indication only.

Patients should confirm their eligibility directly with BC PharmaCare or their prescribing physician.

What This Federal-Provincial Deal Cost — and Who Pays

The $670 million commitment covers both federal and provincial contributions over the initial implementation period. The federal government has committed to covering 100% of the incremental costs for the covered drug categories during the transition, making this a significant incentive for provinces to join.

For patients, the practical result is straightforward: if you live in BC and are prescribed a covered medication, you pay $0 at the pharmacy counter, regardless of whether you have private insurance. The pharmacare plan acts as a universal first payer for the covered categories.

Why GLP-1 Medications Remain Expensive for Most Canadians

Despite this progress, the cost burden of GLP-1 medications for weight management remains largely unchanged for most Canadians outside the new pharmacare coverage. Current retail prices across Canada:

• Ozempic 1mg — approximately $250–$310/month depending on pharmacy and province
• Wegovy 2.4mg — approximately $380–$450/month
• Mounjaro (tirzepatide) — approximately $300–$400/month

Provincial drug benefit programs vary widely in their GLP-1 coverage. Several provinces cover Ozempic for type 2 diabetes through their provincial formularies, but coverage for weight-management-approved doses and drugs remains inconsistent.

What About Generic Semaglutide?

Health Canada is currently reviewing applications from multiple manufacturers for generic versions of semaglutide. Industry analysts expect the first generic approvals in Canada in mid-to-late 2026. If approved, generic semaglutide could reduce costs significantly — potentially to $60–$100/month — and would likely be eligible for coverage under pharmacare frameworks far more easily than brand-name products.

Canadians waiting for lower-cost GLP-1 options can sign up for price alerts on our generic semaglutide waitlist to be notified when generic options become available in their province.

Will Other Provinces Follow BC?

As of March 2026, BC is the only province with a signed implementation agreement. The federal government has indicated it is in active negotiations with several other provinces, with Ontario and Manitoba reported to be the closest to signing. Quebec has historically managed its own drug insurance system and has been cautious about federal pharmacare involvement.

Each provincial agreement will need to be negotiated individually, meaning coverage may look different — and roll out on different timelines — across the country.